Published in Oncologist on August 05, 2013
Tirosine kinase inhibitors adverse events. Oncologist (2014) 0.87
The Utility of Exercise Testing in Patients with Lung Cancer. J Thorac Oncol (2016) 0.78
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemother Pharmacol (2016) 0.78
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. PLoS One (2015) 0.77
Inhibition of proto-oncogene c-Src tyrosine kinase: toward a new antiarrhythmic strategy? J Am Coll Cardiol (2014) 0.75
In reply. Oncologist (2014) 0.75
Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs. Eur J Clin Pharmacol (2015) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86
What clinicians should know about the QT interval. JAMA (2003) 4.45
An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Am J Cardiol (1992) 3.66
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol (2006) 2.52
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol (2010) 2.18
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension (2009) 1.88
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol (2007) 1.61
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci (2009) 1.28
Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol (2007) 1.28
The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol (2003) 1.25
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol (2012) 1.24
Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol (2003) 1.15
Clinical cardiac safety profile of nilotinib. Haematologica (2012) 1.13
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J (2002) 1.05
Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis (2010) 0.98
Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. Drug Discov Today (2008) 0.97
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol (2008) 0.94
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep (2009) 0.94
Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail (2000) 0.87
Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol (2000) 0.87
Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis (2010) 0.87
The duration of the electrical systole, Q-T, in acute rheumatic carditis in children. Am Heart J (1947) 0.86
The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting. Heart Fail Clin (2011) 0.84
Statistical characterization of QT prolongation. J Biopharm Stat (2010) 0.83
Torsade de pointes and long QT syndrome following major blood transfusion. Anaesthesia (1992) 0.79
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med (2012) 2.08
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J (2013) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol (2003) 1.81
The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol (2007) 1.77
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J (2009) 1.66
L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol (2006) 1.57
Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation (2004) 1.57
L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm (2007) 1.48
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. Heart Rhythm (2012) 1.44
Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy. Circ Arrhythm Electrophysiol (2009) 1.43
The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol (2009) 1.21
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Dronedarone. Circulation (2009) 1.14
Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol (2010) 1.11
The QT and Tp-e intervals in left and right chest leads: comparison between patients with systemic and pulmonary hypertension. J Electrocardiol (2005) 1.06
Electrical failure of an ICD lead due to a presumed insulation defect only diagnosed by a maximum output shock. Pacing Clin Electrophysiol (2013) 1.06
ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol (2005) 1.02
Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J (2012) 1.01
Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J (2009) 0.99
First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol (2005) 0.99
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes (2013) 0.97
Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit. Am J Physiol Heart Circ Physiol (2008) 0.96
Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol (2011) 0.96
A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol (2010) 0.94
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. Heart Rhythm (2010) 0.92
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol (2009) 0.89
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol (2005) 0.88
Fast-track training of nonelectrophysiologists to implant defibrillators: is it needed? Pacing Clin Electrophysiol (2006) 0.87
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J (2009) 0.86
Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol (2008) 0.85
The electrocardiographic manifestations of arrhythmogenic right ventricular dysplasia. Curr Cardiol Rev (2014) 0.83
Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2002) 0.83
Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol (2005) 0.82
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin Exp Pharmacol Physiol (2012) 0.81
The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis (2004) 0.81
Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol (2009) 0.80
Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs. Cardiovasc Toxicol (2009) 0.80
Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol (2010) 0.80
Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J Cardiovasc Electrophysiol (2004) 0.80
Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol (2009) 0.79
Proarrhythmias and antiarrhythmias: two sides of the same coin. Heart Rhythm (2005) 0.79
Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Curr Opin Cardiol (2006) 0.78
Stroke prevention in atrial fibrillation. J Cardiovasc Med (Hagerstown) (2012) 0.78
Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol (2003) 0.77
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol (2008) 0.77
Atrial fibrillation: pharmacological therapy. Curr Probl Cardiol (2011) 0.76
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm (2011) 0.76
Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol (2011) 0.76
Drug therapy for atrial fibrillation. Med Clin North Am (2008) 0.76
Future directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol (2006) 0.75
Boldly monitoring where few people have monitored before. Cardiology (2008) 0.75
In reply. Oncologist (2014) 0.75
"Doctor, why didn't you tell me about this before the ICD?". J Cardiovasc Electrophysiol (2006) 0.75
The meta-analysis: supportive or illuminating? Eur Heart J (2006) 0.75
Making a silk purse out of a sow's ear. J Am Coll Cardiol (2005) 0.75
Thoroughly measuring the QT interval: can we find the shortcuts? Heart Rhythm (2011) 0.75
Discarding the baby with the bathwater. Pacing Clin Electrophysiol (2007) 0.75
Drug-induced long-QT syndrome and torsade de pointes: an underrated problem? Europace (2013) 0.75
The reply. Am J Med (2013) 0.75
Born to be bradycardic? Cardiology (2010) 0.75
You only get so many heartbeats... J Am Coll Cardiol (2004) 0.75
What's a mother to do? J Cardiovasc Electrophysiol (2011) 0.75
Response to Pasquale Santangeli, MD, Luigi Di Biase, MD, PhD, Andrea Natale, MD. Circ Arrhythm Electrophysiol (2014) 0.75
Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol (2007) 0.75
A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol (2004) 0.75
Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. Cardiology (2016) 0.75
Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy. Heart Fail Clin (2011) 0.75
Why did you order that echocardiogram? Clin Cardiol (2010) 0.75
The unnecessary pacemaker controversy revisited. Pacing Clin Electrophysiol (2002) 0.75
Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose? Clin Cardiol (2013) 0.75
The geriatric paradox. Am J Geriatr Cardiol (2008) 0.75
Antiarrhythmic drug therapy. Curr Treat Options Cardiovasc Med (2006) 0.75
Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management. Clin Cardiol (2005) 0.75
Adjuvant therapy for atrial fibrillation. Future Cardiol (2010) 0.75
Reversal of fortunes: recognizing misplacement of ECG electrodes. Am J Med (2013) 0.75
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol (2014) 0.75
Ischemia versus amiodarone induced polymorphic ventricular tachycardia. Pacing Clin Electrophysiol (2002) 0.75
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. J Cardiovasc Electrophysiol (2014) 0.75
Drug therapy for atrial fibrillation. Cardiol Clin (2009) 0.75
Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circ Heart Fail (2010) 0.75
Pharmacologic therapies for atrial fibrillation. Am J Geriatr Cardiol (2005) 0.75